John Imig
Concepts (549)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Epoxide Hydrolases | 44 | 2024 | 49 | 10.970 |
Why?
| Hypertension | 66 | 2023 | 565 | 10.450 |
Why?
| Kidney | 61 | 2024 | 822 | 8.060 |
Why?
| Kidney Diseases | 22 | 2021 | 293 | 7.220 |
Why?
| 8,11,14-Eicosatrienoic Acid | 19 | 2021 | 19 | 5.100 |
Why?
| Cytochrome P-450 Enzyme System | 27 | 2020 | 192 | 4.890 |
Why?
| Blood Pressure | 56 | 2021 | 587 | 4.780 |
Why?
| Eicosanoids | 15 | 2022 | 19 | 4.260 |
Why?
| Vasodilation | 26 | 2020 | 106 | 4.070 |
Why?
| Renal Insufficiency, Chronic | 9 | 2024 | 182 | 3.440 |
Why?
| Ureteral Obstruction | 6 | 2024 | 70 | 3.430 |
Why?
| Rats | 90 | 2021 | 3419 | 3.340 |
Why?
| Animals | 143 | 2024 | 14409 | 3.270 |
Why?
| Antihypertensive Agents | 20 | 2023 | 139 | 3.090 |
Why?
| Hydroxyeicosatetraenoic Acids | 15 | 2020 | 20 | 2.850 |
Why?
| Cardiovascular Diseases | 9 | 2023 | 476 | 2.730 |
Why?
| Angiotensin II | 32 | 2019 | 167 | 2.710 |
Why?
| Diabetic Nephropathies | 9 | 2021 | 77 | 2.610 |
Why?
| Endothelium, Vascular | 13 | 2016 | 288 | 2.590 |
Why?
| Arachidonic Acids | 9 | 2019 | 26 | 2.350 |
Why?
| Diabetes Mellitus, Experimental | 8 | 2021 | 140 | 2.290 |
Why?
| Enzyme Inhibitors | 20 | 2021 | 446 | 2.200 |
Why?
| Sodium Chloride, Dietary | 11 | 2023 | 33 | 2.080 |
Why?
| Nephritis | 6 | 2024 | 27 | 2.070 |
Why?
| Obesity | 13 | 2018 | 1203 | 1.970 |
Why?
| PPAR gamma | 4 | 2020 | 81 | 1.850 |
Why?
| Epoxy Compounds | 5 | 2021 | 48 | 1.750 |
Why?
| Rats, Sprague-Dawley | 47 | 2018 | 1664 | 1.740 |
Why?
| Diabetes Mellitus, Type 2 | 7 | 2021 | 486 | 1.620 |
Why?
| Oxidative Stress | 14 | 2021 | 958 | 1.600 |
Why?
| Fibrosis | 10 | 2024 | 209 | 1.580 |
Why?
| Lauric Acids | 5 | 2009 | 8 | 1.530 |
Why?
| Inflammation | 14 | 2024 | 678 | 1.520 |
Why?
| Male | 97 | 2024 | 27347 | 1.500 |
Why?
| Mesenteric Arteries | 9 | 2017 | 45 | 1.490 |
Why?
| Arterioles | 14 | 2018 | 35 | 1.480 |
Why?
| Adamantane | 5 | 2009 | 33 | 1.460 |
Why?
| Fatty Acids | 3 | 2023 | 175 | 1.460 |
Why?
| Kidney Glomerulus | 8 | 2018 | 61 | 1.450 |
Why?
| Renal Circulation | 13 | 2019 | 82 | 1.450 |
Why?
| Benzimidazoles | 6 | 2014 | 54 | 1.430 |
Why?
| Vasodilator Agents | 9 | 2018 | 111 | 1.420 |
Why?
| Disease Models, Animal | 23 | 2024 | 1647 | 1.420 |
Why?
| Blood Glucose | 9 | 2021 | 489 | 1.400 |
Why?
| Sodium Chloride | 6 | 2020 | 67 | 1.330 |
Why?
| Mice | 35 | 2024 | 6428 | 1.280 |
Why?
| Myocardial Infarction | 5 | 2021 | 423 | 1.280 |
Why?
| Rats, Inbred SHR | 11 | 2020 | 33 | 1.190 |
Why?
| Hypertension, Renal | 6 | 2016 | 22 | 1.110 |
Why?
| Myocardium | 5 | 2021 | 443 | 1.040 |
Why?
| Oxadiazoles | 3 | 2014 | 13 | 1.030 |
Why?
| Arachidonic Acid | 12 | 2020 | 39 | 1.010 |
Why?
| Albuminuria | 12 | 2018 | 42 | 1.000 |
Why?
| Acute Kidney Injury | 5 | 2022 | 404 | 1.000 |
Why?
| Benzoates | 8 | 2014 | 22 | 0.990 |
Why?
| Collagen | 5 | 2024 | 223 | 0.910 |
Why?
| Phosphates | 1 | 2022 | 51 | 0.870 |
Why?
| Cyclooxygenase 2 | 5 | 2016 | 49 | 0.840 |
Why?
| Bradykinin | 3 | 2015 | 20 | 0.820 |
Why?
| Virus Diseases | 1 | 2022 | 44 | 0.820 |
Why?
| Dietary Fats | 4 | 2011 | 142 | 0.810 |
Why?
| Hydroxyproline | 2 | 2024 | 20 | 0.810 |
Why?
| Mice, Inbred C57BL | 16 | 2024 | 2001 | 0.810 |
Why?
| Rats, Inbred WKY | 8 | 2021 | 29 | 0.800 |
Why?
| Metabolic Diseases | 1 | 2021 | 44 | 0.780 |
Why?
| Vasoconstriction | 12 | 2019 | 60 | 0.770 |
Why?
| Myocardial Reperfusion Injury | 2 | 2018 | 49 | 0.760 |
Why?
| Humans | 42 | 2023 | 54391 | 0.750 |
Why?
| Prostaglandin-Endoperoxide Synthases | 5 | 2016 | 26 | 0.750 |
Why?
| Water-Electrolyte Balance | 1 | 2020 | 40 | 0.740 |
Why?
| Muscle, Smooth, Vascular | 9 | 2021 | 140 | 0.740 |
Why?
| Blood Vessels | 1 | 2020 | 78 | 0.740 |
Why?
| Renin-Angiotensin System | 9 | 2019 | 65 | 0.740 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 142 | 0.710 |
Why?
| Rats, Zucker | 8 | 2018 | 74 | 0.700 |
Why?
| Urea | 7 | 2014 | 83 | 0.700 |
Why?
| Kidney Transplantation | 1 | 2021 | 189 | 0.690 |
Why?
| Liver Cirrhosis | 2 | 2018 | 218 | 0.690 |
Why?
| Fatty Acids, Omega-3 | 2 | 2016 | 29 | 0.670 |
Why?
| Heart Diseases | 1 | 2021 | 239 | 0.670 |
Why?
| Proteinuria | 3 | 2016 | 52 | 0.660 |
Why?
| Isoenzymes | 5 | 2006 | 177 | 0.650 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 60 | 0.640 |
Why?
| Insulin Resistance | 6 | 2018 | 300 | 0.640 |
Why?
| Nitric Oxide | 5 | 2016 | 298 | 0.640 |
Why?
| Cyclooxygenase 2 Inhibitors | 2 | 2016 | 20 | 0.630 |
Why?
| Ventricular Remodeling | 1 | 2018 | 65 | 0.630 |
Why?
| Renin | 7 | 2016 | 23 | 0.630 |
Why?
| Rats, Transgenic | 15 | 2019 | 19 | 0.620 |
Why?
| Drug Discovery | 1 | 2018 | 90 | 0.610 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 4 | 2018 | 46 | 0.600 |
Why?
| Ventricular Function, Left | 1 | 2018 | 182 | 0.590 |
Why?
| Membrane Proteins | 3 | 2015 | 389 | 0.590 |
Why?
| Solubility | 5 | 2022 | 75 | 0.590 |
Why?
| Natriuresis | 4 | 2020 | 7 | 0.580 |
Why?
| Superoxides | 2 | 2016 | 61 | 0.570 |
Why?
| Kidney Failure, Chronic | 2 | 2009 | 232 | 0.570 |
Why?
| Fatty Acids, Unsaturated | 1 | 2016 | 46 | 0.560 |
Why?
| Neuroprotective Agents | 2 | 2009 | 125 | 0.560 |
Why?
| Microcirculation | 11 | 2016 | 89 | 0.560 |
Why?
| Arachidonate Lipoxygenases | 1 | 2015 | 1 | 0.560 |
Why?
| Aminopeptidases | 1 | 2015 | 18 | 0.550 |
Why?
| Cisplatin | 2 | 2021 | 351 | 0.540 |
Why?
| Brain Ischemia | 2 | 2009 | 169 | 0.540 |
Why?
| Sodium | 6 | 2023 | 102 | 0.540 |
Why?
| Cerebral Arteries | 1 | 2015 | 37 | 0.530 |
Why?
| Angiotensins | 3 | 2010 | 12 | 0.520 |
Why?
| Metabolome | 1 | 2016 | 109 | 0.520 |
Why?
| Macrophages | 7 | 2021 | 404 | 0.520 |
Why?
| Sodium Channel Blockers | 1 | 2014 | 18 | 0.510 |
Why?
| Cardiomegaly | 3 | 2021 | 38 | 0.510 |
Why?
| Signal Transduction | 11 | 2018 | 1752 | 0.510 |
Why?
| Tetrazoles | 5 | 2014 | 43 | 0.510 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 314 | 0.500 |
Why?
| Protective Agents | 1 | 2014 | 20 | 0.490 |
Why?
| Gene Expression | 3 | 2015 | 664 | 0.490 |
Why?
| Lipids | 5 | 2023 | 178 | 0.490 |
Why?
| Hypertension, Renovascular | 4 | 2016 | 16 | 0.480 |
Why?
| Endothelial Cells | 2 | 2013 | 294 | 0.480 |
Why?
| Homeostasis | 5 | 2016 | 223 | 0.480 |
Why?
| Rats, Inbred Dahl | 6 | 2021 | 10 | 0.470 |
Why?
| Captopril | 2 | 2016 | 13 | 0.470 |
Why?
| Large-Conductance Calcium-Activated Potassium Channels | 3 | 2013 | 13 | 0.460 |
Why?
| Acetylcholine | 5 | 2016 | 53 | 0.450 |
Why?
| Kidney Tubules, Proximal | 4 | 2013 | 119 | 0.450 |
Why?
| Cyclooxygenase Inhibitors | 3 | 2016 | 44 | 0.450 |
Why?
| Enalapril | 3 | 2021 | 16 | 0.440 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2010 | 435 | 0.440 |
Why?
| Cerebrovascular Circulation | 2 | 2011 | 137 | 0.440 |
Why?
| Cyclic N-Oxides | 2 | 2009 | 15 | 0.440 |
Why?
| Calcium | 5 | 2021 | 434 | 0.430 |
Why?
| Benzenesulfonates | 1 | 2012 | 12 | 0.430 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 82 | 0.430 |
Why?
| Growth Inhibitors | 1 | 2012 | 32 | 0.430 |
Why?
| Thiazolidinediones | 1 | 2012 | 95 | 0.420 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2012 | 14 | 0.420 |
Why?
| Vasoconstrictor Agents | 7 | 2019 | 88 | 0.420 |
Why?
| Hypertension, Malignant | 3 | 2018 | 5 | 0.420 |
Why?
| Immunologic Factors | 1 | 2013 | 130 | 0.420 |
Why?
| Sulfones | 3 | 2010 | 24 | 0.410 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2012 | 232 | 0.410 |
Why?
| Hypoglycemic Agents | 2 | 2012 | 177 | 0.400 |
Why?
| Endoplasmic Reticulum Stress | 4 | 2017 | 42 | 0.400 |
Why?
| Pyridines | 2 | 2012 | 137 | 0.400 |
Why?
| Breast Neoplasms | 1 | 2021 | 1249 | 0.400 |
Why?
| Apoptosis | 8 | 2019 | 1302 | 0.400 |
Why?
| NG-Nitroarginine Methyl Ester | 3 | 2016 | 21 | 0.400 |
Why?
| Chemokine CCL2 | 7 | 2011 | 79 | 0.400 |
Why?
| Dose-Response Relationship, Drug | 10 | 2019 | 1476 | 0.390 |
Why?
| Potassium Channels | 3 | 2012 | 41 | 0.390 |
Why?
| Valine | 1 | 2011 | 54 | 0.380 |
Why?
| Drug Delivery Systems | 2 | 2009 | 151 | 0.380 |
Why?
| Arrhythmias, Cardiac | 3 | 2021 | 99 | 0.370 |
Why?
| Receptors, Adrenergic, alpha-2 | 1 | 2009 | 3 | 0.360 |
Why?
| Actins | 2 | 2024 | 132 | 0.360 |
Why?
| Simvastatin | 1 | 2009 | 35 | 0.360 |
Why?
| Mice, Knockout | 10 | 2021 | 927 | 0.350 |
Why?
| Oleic Acids | 1 | 2009 | 11 | 0.350 |
Why?
| Potassium, Dietary | 1 | 2009 | 2 | 0.350 |
Why?
| Oxidoreductases | 2 | 2008 | 62 | 0.340 |
Why?
| PPAR alpha | 2 | 2006 | 64 | 0.340 |
Why?
| Thrombosis | 2 | 2022 | 243 | 0.340 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2011 | 202 | 0.340 |
Why?
| Cytochrome P-450 CYP1A1 | 5 | 2018 | 46 | 0.330 |
Why?
| Gene Deletion | 2 | 2009 | 293 | 0.330 |
Why?
| Receptor, Angiotensin, Type 1 | 4 | 2005 | 61 | 0.330 |
Why?
| Hypnotics and Sedatives | 1 | 2009 | 74 | 0.330 |
Why?
| Sulfonamides | 2 | 2022 | 146 | 0.320 |
Why?
| Potassium Channels, Calcium-Activated | 2 | 2007 | 5 | 0.310 |
Why?
| Receptors, CCR2 | 1 | 2007 | 14 | 0.310 |
Why?
| Carrier Proteins | 2 | 2013 | 360 | 0.310 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 674 | 0.310 |
Why?
| Body Weight | 4 | 2014 | 578 | 0.300 |
Why?
| Receptors, Prostaglandin E | 2 | 2007 | 2 | 0.300 |
Why?
| Gene Expression Regulation | 3 | 2016 | 1063 | 0.300 |
Why?
| Nitric Oxide Synthase | 4 | 2016 | 102 | 0.300 |
Why?
| Hemodynamics | 3 | 2015 | 291 | 0.300 |
Why?
| Calcium Channels | 2 | 2005 | 59 | 0.300 |
Why?
| Phosphoprotein Phosphatases | 1 | 2006 | 20 | 0.290 |
Why?
| Drug Evaluation, Preclinical | 4 | 2018 | 158 | 0.290 |
Why?
| Disease Progression | 5 | 2015 | 915 | 0.290 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 85 | 0.290 |
Why?
| Glucose Tolerance Test | 2 | 2018 | 67 | 0.280 |
Why?
| Cholesterol | 3 | 2014 | 155 | 0.280 |
Why?
| Immunoglobulin G | 2 | 2007 | 227 | 0.280 |
Why?
| Fenofibrate | 1 | 2006 | 16 | 0.280 |
Why?
| Heme Oxygenase-1 | 2 | 2019 | 21 | 0.280 |
Why?
| Hypolipidemic Agents | 1 | 2006 | 33 | 0.280 |
Why?
| Purinergic P2 Receptor Agonists | 2 | 2005 | 4 | 0.270 |
Why?
| Cerebral Infarction | 1 | 2005 | 32 | 0.270 |
Why?
| Hyperglycemia | 2 | 2017 | 83 | 0.260 |
Why?
| Chloride Channels | 2 | 2021 | 29 | 0.260 |
Why?
| NF-kappa B | 5 | 2013 | 336 | 0.260 |
Why?
| RNA, Messenger | 6 | 2007 | 1203 | 0.260 |
Why?
| Insulin | 5 | 2014 | 511 | 0.260 |
Why?
| Adenosine Triphosphate | 3 | 2005 | 242 | 0.260 |
Why?
| Lactones | 1 | 2004 | 27 | 0.250 |
Why?
| Islets of Langerhans | 2 | 2017 | 23 | 0.250 |
Why?
| Heart Failure | 2 | 2021 | 541 | 0.250 |
Why?
| Kidney Cortex | 5 | 2007 | 38 | 0.250 |
Why?
| Administration, Oral | 5 | 2017 | 461 | 0.240 |
Why?
| Biological Factors | 1 | 2004 | 13 | 0.240 |
Why?
| Heart | 2 | 2019 | 361 | 0.240 |
Why?
| Osteonectin | 3 | 2008 | 11 | 0.240 |
Why?
| Rats, Inbred Strains | 3 | 2015 | 172 | 0.240 |
Why?
| Hypertrophy | 1 | 2024 | 55 | 0.240 |
Why?
| Cell Line, Tumor | 3 | 2021 | 1551 | 0.240 |
Why?
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2003 | 2 | 0.240 |
Why?
| Dinoprostone | 2 | 2007 | 55 | 0.240 |
Why?
| Fibroblasts | 3 | 2021 | 386 | 0.240 |
Why?
| Phenylurea Compounds | 2 | 2014 | 16 | 0.240 |
Why?
| Receptor, Bradykinin B2 | 1 | 2003 | 9 | 0.240 |
Why?
| Time Factors | 8 | 2016 | 3210 | 0.230 |
Why?
| Thiobarbituric Acid Reactive Substances | 3 | 2013 | 12 | 0.220 |
Why?
| Osteopontin | 1 | 2022 | 16 | 0.220 |
Why?
| Alprostadil | 1 | 2002 | 12 | 0.220 |
Why?
| Diet, High-Fat | 3 | 2021 | 216 | 0.220 |
Why?
| Minerals | 1 | 2022 | 36 | 0.220 |
Why?
| Steroid 16-alpha-Hydroxylase | 4 | 2016 | 6 | 0.210 |
Why?
| Carbazoles | 1 | 2022 | 16 | 0.210 |
Why?
| Amides | 4 | 2018 | 43 | 0.210 |
Why?
| Sex Characteristics | 1 | 2024 | 214 | 0.210 |
Why?
| Substance P | 1 | 2021 | 26 | 0.210 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2016 | 70 | 0.210 |
Why?
| Tachycardia, Ventricular | 1 | 2021 | 43 | 0.200 |
Why?
| Adaptation, Physiological | 1 | 2002 | 103 | 0.200 |
Why?
| Inflammation Mediators | 3 | 2013 | 128 | 0.200 |
Why?
| Desoxycorticosterone | 3 | 2009 | 5 | 0.200 |
Why?
| Isoprostanes | 1 | 2020 | 3 | 0.200 |
Why?
| Vascular Stiffness | 1 | 2021 | 20 | 0.190 |
Why?
| I-kappa B Kinase | 2 | 2011 | 29 | 0.190 |
Why?
| Paracrine Communication | 1 | 2020 | 12 | 0.190 |
Why?
| Tumor Burden | 1 | 2021 | 141 | 0.190 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 219 | 0.190 |
Why?
| Mice, Nude | 1 | 2021 | 284 | 0.190 |
Why?
| Water-Electrolyte Imbalance | 1 | 2020 | 17 | 0.190 |
Why?
| Peptides | 2 | 2015 | 276 | 0.190 |
Why?
| Potassium | 1 | 2020 | 60 | 0.190 |
Why?
| Down-Regulation | 3 | 2018 | 388 | 0.190 |
Why?
| Muscle Contraction | 1 | 2021 | 111 | 0.180 |
Why?
| Metabolic Networks and Pathways | 1 | 2020 | 104 | 0.180 |
Why?
| Risk | 1 | 2021 | 343 | 0.180 |
Why?
| Receptors, Neurokinin-1 | 1 | 2019 | 12 | 0.180 |
Why?
| Renal Dialysis | 1 | 2021 | 193 | 0.180 |
Why?
| Forecasting | 1 | 2020 | 161 | 0.180 |
Why?
| Chenodeoxycholic Acid | 1 | 2019 | 8 | 0.180 |
Why?
| Endothelin-1 | 5 | 2008 | 30 | 0.180 |
Why?
| Golgi Apparatus | 1 | 2021 | 120 | 0.170 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2012 | 84 | 0.170 |
Why?
| Mast Cells | 1 | 2019 | 64 | 0.170 |
Why?
| KATP Channels | 1 | 2018 | 6 | 0.170 |
Why?
| Cardiotonic Agents | 2 | 2012 | 95 | 0.170 |
Why?
| 3' Untranslated Regions | 1 | 2018 | 57 | 0.170 |
Why?
| Drug Therapy, Combination | 4 | 2018 | 426 | 0.160 |
Why?
| Proteolysis | 1 | 2018 | 102 | 0.160 |
Why?
| Weight Gain | 3 | 2010 | 244 | 0.160 |
Why?
| Protein Phosphatase 2 | 2 | 2008 | 6 | 0.160 |
Why?
| Muscle Cells | 2 | 2008 | 24 | 0.150 |
Why?
| Receptor, Cannabinoid, CB1 | 2 | 2009 | 128 | 0.150 |
Why?
| Antioxidants | 3 | 2009 | 297 | 0.150 |
Why?
| Epithelial Sodium Channels | 2 | 2013 | 10 | 0.150 |
Why?
| Fatty Liver | 1 | 2018 | 129 | 0.150 |
Why?
| Blood Urea Nitrogen | 2 | 2016 | 51 | 0.150 |
Why?
| Female | 11 | 2024 | 28471 | 0.150 |
Why?
| Carcinoma | 2 | 2008 | 154 | 0.140 |
Why?
| Vascular Resistance | 2 | 2006 | 60 | 0.140 |
Why?
| Species Specificity | 2 | 2016 | 206 | 0.140 |
Why?
| Indomethacin | 1 | 2016 | 40 | 0.140 |
Why?
| Stereoisomerism | 1 | 2016 | 106 | 0.140 |
Why?
| Cyclosporine | 1 | 2016 | 66 | 0.140 |
Why?
| Podocytes | 2 | 2017 | 25 | 0.140 |
Why?
| Renal Artery | 1 | 2016 | 40 | 0.140 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 53 | 0.140 |
Why?
| Receptor, Adenosine A2B | 1 | 2015 | 3 | 0.140 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 491 | 0.130 |
Why?
| Ion Channel Gating | 2 | 2006 | 47 | 0.130 |
Why?
| Phosphorylation | 3 | 2013 | 613 | 0.130 |
Why?
| Epigenesis, Genetic | 1 | 2018 | 399 | 0.130 |
Why?
| Whole-Body Irradiation | 1 | 2016 | 161 | 0.130 |
Why?
| Nephrosclerosis | 1 | 2014 | 7 | 0.130 |
Why?
| Cytokines | 3 | 2021 | 677 | 0.130 |
Why?
| Radiation Injuries, Experimental | 1 | 2016 | 105 | 0.130 |
Why?
| Glucose | 2 | 2021 | 366 | 0.130 |
Why?
| Receptors, Purinergic P2 | 2 | 2005 | 37 | 0.130 |
Why?
| Hypertrophy, Left Ventricular | 1 | 2014 | 40 | 0.120 |
Why?
| Radiation-Protective Agents | 1 | 2016 | 116 | 0.120 |
Why?
| Immunosuppressive Agents | 1 | 2016 | 248 | 0.120 |
Why?
| Calcium Signaling | 2 | 2005 | 59 | 0.120 |
Why?
| Glucose Intolerance | 1 | 2014 | 28 | 0.120 |
Why?
| Fructose | 1 | 2013 | 29 | 0.120 |
Why?
| Caspase Inhibitors | 1 | 2013 | 31 | 0.120 |
Why?
| Myocytes, Smooth Muscle | 3 | 2021 | 92 | 0.120 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 206 | 0.120 |
Why?
| Coronary Vessels | 2 | 2014 | 197 | 0.120 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 474 | 0.120 |
Why?
| Eye Diseases | 1 | 2013 | 35 | 0.120 |
Why?
| Receptor, Endothelin A | 2 | 2019 | 8 | 0.120 |
Why?
| Cross-Linking Reagents | 1 | 2013 | 42 | 0.110 |
Why?
| Triglycerides | 1 | 2014 | 195 | 0.110 |
Why?
| Cell Survival | 2 | 2013 | 657 | 0.110 |
Why?
| Retina | 1 | 2013 | 65 | 0.110 |
Why?
| Inflammasomes | 1 | 2013 | 60 | 0.110 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 95 | 0.110 |
Why?
| Rats, Wistar | 2 | 2013 | 237 | 0.110 |
Why?
| Creatinine | 1 | 2013 | 169 | 0.110 |
Why?
| Nephrectomy | 3 | 2019 | 93 | 0.110 |
Why?
| Indoles | 4 | 2018 | 289 | 0.110 |
Why?
| Cyclic AMP | 2 | 2015 | 106 | 0.110 |
Why?
| Spin Labels | 2 | 2009 | 7 | 0.110 |
Why?
| Superoxide Dismutase | 1 | 2013 | 125 | 0.110 |
Why?
| Angiotensin I | 3 | 2016 | 15 | 0.110 |
Why?
| HEK293 Cells | 1 | 2013 | 245 | 0.110 |
Why?
| Small Molecule Libraries | 1 | 2013 | 72 | 0.110 |
Why?
| Structure-Activity Relationship | 2 | 2017 | 423 | 0.110 |
Why?
| Niacinamide | 1 | 2012 | 25 | 0.110 |
Why?
| HeLa Cells | 1 | 2013 | 291 | 0.110 |
Why?
| Interleukin-6 | 3 | 2015 | 315 | 0.110 |
Why?
| Receptors, Angiotensin | 2 | 2002 | 12 | 0.110 |
Why?
| Immunity, Innate | 1 | 2013 | 114 | 0.110 |
Why?
| Syndrome | 1 | 2012 | 253 | 0.100 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 158 | 0.100 |
Why?
| Blotting, Western | 4 | 2010 | 684 | 0.100 |
Why?
| Platelet Aggregation | 1 | 2012 | 82 | 0.100 |
Why?
| Transcription Factor RelA | 1 | 2011 | 30 | 0.100 |
Why?
| Anti-Inflammatory Agents | 1 | 2013 | 175 | 0.100 |
Why?
| Neovascularization, Physiologic | 1 | 2012 | 72 | 0.100 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2011 | 7 | 0.100 |
Why?
| Catalase | 1 | 2011 | 74 | 0.100 |
Why?
| Cell Adhesion Molecules | 1 | 2011 | 87 | 0.100 |
Why?
| Receptors, Purinergic P2X | 3 | 2005 | 6 | 0.100 |
Why?
| Hydralazine | 2 | 2014 | 5 | 0.090 |
Why?
| Reserpine | 2 | 2014 | 13 | 0.090 |
Why?
| Hydrochlorothiazide | 2 | 2014 | 6 | 0.090 |
Why?
| Kidney Function Tests | 1 | 2010 | 59 | 0.090 |
Why?
| Nitrites | 1 | 2010 | 39 | 0.090 |
Why?
| Pyrrolidines | 3 | 2005 | 88 | 0.090 |
Why?
| Biphenyl Compounds | 3 | 2005 | 30 | 0.090 |
Why?
| Models, Biological | 2 | 2021 | 825 | 0.090 |
Why?
| Multiple Organ Failure | 1 | 2010 | 56 | 0.090 |
Why?
| Cells, Cultured | 3 | 2011 | 1737 | 0.090 |
Why?
| Molecular Targeted Therapy | 1 | 2010 | 128 | 0.090 |
Why?
| Receptors, Tumor Necrosis Factor | 2 | 2007 | 36 | 0.090 |
Why?
| Dietary Supplements | 1 | 2013 | 457 | 0.090 |
Why?
| Epithelial Cells | 1 | 2011 | 255 | 0.090 |
Why?
| TRPV Cation Channels | 1 | 2009 | 7 | 0.090 |
Why?
| Microvessels | 1 | 2009 | 34 | 0.090 |
Why?
| Cardiovascular Agents | 1 | 2009 | 60 | 0.090 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2007 | 64 | 0.090 |
Why?
| Receptors, Cannabinoid | 1 | 2009 | 20 | 0.090 |
Why?
| Mice, Obese | 1 | 2009 | 22 | 0.090 |
Why?
| Endothelins | 2 | 2005 | 19 | 0.090 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 289 | 0.080 |
Why?
| Aorta | 2 | 2007 | 177 | 0.080 |
Why?
| Receptors, CCR1 | 1 | 2007 | 10 | 0.080 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 150 | 0.080 |
Why?
| Cattle | 3 | 2014 | 225 | 0.080 |
Why?
| Ascitic Fluid | 1 | 2007 | 13 | 0.080 |
Why?
| Capillaries | 2 | 2005 | 58 | 0.080 |
Why?
| Receptor, Cannabinoid, CB2 | 1 | 2008 | 60 | 0.080 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 75 | 0.080 |
Why?
| Cell Separation | 2 | 2005 | 107 | 0.080 |
Why?
| Oxygenases | 2 | 2007 | 10 | 0.080 |
Why?
| Glomerular Filtration Rate | 3 | 2013 | 139 | 0.080 |
Why?
| Norepinephrine | 2 | 2010 | 119 | 0.070 |
Why?
| Charybdotoxin | 1 | 2006 | 1 | 0.070 |
Why?
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2006 | 6 | 0.070 |
Why?
| Okadaic Acid | 1 | 2006 | 9 | 0.070 |
Why?
| Angiotensin Receptor Antagonists | 2 | 2004 | 23 | 0.070 |
Why?
| Adult | 1 | 2023 | 14207 | 0.070 |
Why?
| Tetraethylammonium Compounds | 1 | 2006 | 1 | 0.070 |
Why?
| Peritoneal Neoplasms | 1 | 2007 | 61 | 0.070 |
Why?
| Triazoles | 1 | 2007 | 119 | 0.070 |
Why?
| Leptin | 1 | 2007 | 154 | 0.070 |
Why?
| Arteries | 1 | 2007 | 101 | 0.070 |
Why?
| Receptor, Endothelin B | 1 | 2005 | 3 | 0.070 |
Why?
| NADPH-Ferrihemoprotein Reductase | 1 | 2006 | 22 | 0.070 |
Why?
| Penile Erection | 1 | 2006 | 23 | 0.070 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 68 | 0.070 |
Why?
| Immunoblotting | 1 | 2006 | 134 | 0.070 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2005 | 93 | 0.070 |
Why?
| Transcriptional Activation | 1 | 2005 | 134 | 0.070 |
Why?
| Penis | 1 | 2006 | 84 | 0.070 |
Why?
| Cell Count | 1 | 2005 | 181 | 0.070 |
Why?
| Nephrons | 1 | 2004 | 10 | 0.060 |
Why?
| Juxtaglomerular Apparatus | 1 | 2004 | 7 | 0.060 |
Why?
| Molecular Structure | 1 | 2006 | 319 | 0.060 |
Why?
| Peroxisome Proliferator-Activated Receptors | 2 | 2014 | 16 | 0.060 |
Why?
| Thromboxane B2 | 1 | 2004 | 11 | 0.060 |
Why?
| Chemokines | 1 | 2004 | 96 | 0.060 |
Why?
| Spectrometry, Fluorescence | 1 | 2004 | 53 | 0.060 |
Why?
| Linoleic Acid | 1 | 2004 | 15 | 0.060 |
Why?
| Calcium Channels, L-Type | 1 | 2004 | 63 | 0.060 |
Why?
| Suramin | 1 | 2003 | 14 | 0.060 |
Why?
| Lipoxygenase | 1 | 2003 | 2 | 0.060 |
Why?
| Dogs | 1 | 2004 | 216 | 0.060 |
Why?
| Survival Rate | 2 | 2018 | 954 | 0.060 |
Why?
| Cell Death | 2 | 2014 | 223 | 0.060 |
Why?
| Prostaglandins E, Synthetic | 1 | 2002 | 1 | 0.060 |
Why?
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2002 | 1 | 0.060 |
Why?
| Gene Expression Profiling | 1 | 2007 | 1141 | 0.050 |
Why?
| Chemoprevention | 1 | 2022 | 16 | 0.050 |
Why?
| Diabetes Mellitus | 1 | 2006 | 309 | 0.050 |
Why?
| Heart Rate | 1 | 2004 | 358 | 0.050 |
Why?
| Endosomes | 1 | 2002 | 37 | 0.050 |
Why?
| Biological Transport | 2 | 2013 | 195 | 0.050 |
Why?
| Receptors, Leptin | 1 | 2021 | 47 | 0.050 |
Why?
| Up-Regulation | 1 | 2003 | 509 | 0.050 |
Why?
| Regional Blood Flow | 2 | 2011 | 121 | 0.050 |
Why?
| Promoter Regions, Genetic | 2 | 2016 | 520 | 0.050 |
Why?
| Peptide Fragments | 2 | 2016 | 242 | 0.050 |
Why?
| Risk Factors | 1 | 2009 | 3937 | 0.050 |
Why?
| Sodium, Dietary | 1 | 2021 | 27 | 0.050 |
Why?
| Rats, Inbred F344 | 2 | 2014 | 209 | 0.050 |
Why?
| Random Allocation | 2 | 2013 | 312 | 0.050 |
Why?
| Treatment Outcome | 1 | 2011 | 5612 | 0.040 |
Why?
| Arterio-Arterial Fistula | 1 | 2019 | 3 | 0.040 |
Why?
| 3T3 Cells | 1 | 2019 | 52 | 0.040 |
Why?
| Pinacidil | 1 | 2018 | 1 | 0.040 |
Why?
| Phenotype | 1 | 2021 | 819 | 0.040 |
Why?
| Aging | 1 | 2004 | 784 | 0.040 |
Why?
| Pulmonary Artery | 1 | 2019 | 152 | 0.040 |
Why?
| Fatty Acids, Monounsaturated | 1 | 2017 | 15 | 0.040 |
Why?
| Mice, Mutant Strains | 2 | 2007 | 84 | 0.040 |
Why?
| Base Sequence | 2 | 2010 | 719 | 0.040 |
Why?
| Dinoprost | 2 | 2007 | 12 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2010 | 658 | 0.040 |
Why?
| Rats, Inbred BN | 1 | 2016 | 21 | 0.040 |
Why?
| Albumins | 1 | 2016 | 39 | 0.040 |
Why?
| Fas Ligand Protein | 1 | 2016 | 21 | 0.030 |
Why?
| Hydrogen Peroxide | 2 | 2007 | 142 | 0.030 |
Why?
| Cytoprotection | 1 | 2016 | 48 | 0.030 |
Why?
| Adenosine A2 Receptor Agonists | 1 | 2015 | 5 | 0.030 |
Why?
| Aminopyridines | 1 | 2015 | 16 | 0.030 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2015 | 21 | 0.030 |
Why?
| Telemetry | 1 | 2015 | 36 | 0.030 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 40 | 0.030 |
Why?
| Autophagy | 1 | 2017 | 202 | 0.030 |
Why?
| Oxamic Acid | 1 | 2014 | 1 | 0.030 |
Why?
| Chemistry Techniques, Synthetic | 1 | 2014 | 20 | 0.030 |
Why?
| Glomerular Basement Membrane | 1 | 2014 | 13 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 176 | 0.030 |
Why?
| Orchiectomy | 1 | 2014 | 38 | 0.030 |
Why?
| Pressure | 2 | 2006 | 120 | 0.030 |
Why?
| Molecular Mimicry | 1 | 2014 | 64 | 0.030 |
Why?
| Sweetening Agents | 1 | 2013 | 24 | 0.030 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 55 | 0.030 |
Why?
| Necrosis | 1 | 2014 | 208 | 0.030 |
Why?
| Epithelial Sodium Channel Blockers | 1 | 2013 | 3 | 0.030 |
Why?
| Sex Factors | 2 | 2008 | 766 | 0.030 |
Why?
| Cell Proliferation | 2 | 2008 | 1097 | 0.030 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2013 | 25 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2013 | 194 | 0.030 |
Why?
| Mice, Inbred Strains | 1 | 2013 | 199 | 0.030 |
Why?
| Lipid Peroxidation | 1 | 2013 | 132 | 0.030 |
Why?
| Muscle Relaxation | 1 | 2012 | 15 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 198 | 0.030 |
Why?
| Isometric Contraction | 1 | 2012 | 25 | 0.030 |
Why?
| Coronary Circulation | 1 | 2012 | 62 | 0.030 |
Why?
| Amitrole | 1 | 2011 | 1 | 0.030 |
Why?
| Drug Contamination | 1 | 2011 | 4 | 0.030 |
Why?
| Patch-Clamp Techniques | 1 | 2012 | 148 | 0.030 |
Why?
| Membrane Potentials | 1 | 2012 | 139 | 0.030 |
Why?
| Losartan | 1 | 2011 | 28 | 0.030 |
Why?
| Insulin Receptor Substrate Proteins | 1 | 2011 | 11 | 0.030 |
Why?
| Amidines | 1 | 2011 | 8 | 0.030 |
Why?
| Obesity, Abdominal | 1 | 2011 | 12 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2013 | 693 | 0.020 |
Why?
| Renal Plasma Flow | 1 | 2011 | 4 | 0.020 |
Why?
| Pancreas | 1 | 2011 | 80 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2012 | 313 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2010 | 82 | 0.020 |
Why?
| DNA Primers | 1 | 2010 | 225 | 0.020 |
Why?
| Androgens | 1 | 2009 | 68 | 0.020 |
Why?
| U937 Cells | 1 | 2008 | 15 | 0.020 |
Why?
| Chemotaxis, Leukocyte | 1 | 2008 | 20 | 0.020 |
Why?
| Luteinizing Hormone | 1 | 2008 | 14 | 0.020 |
Why?
| Follicle Stimulating Hormone | 1 | 2008 | 26 | 0.020 |
Why?
| Epithelium | 1 | 2008 | 68 | 0.020 |
Why?
| HL-60 Cells | 1 | 2008 | 24 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1504 | 0.020 |
Why?
| Cricetulus | 1 | 2008 | 102 | 0.020 |
Why?
| Estrogen Replacement Therapy | 1 | 2008 | 41 | 0.020 |
Why?
| CHO Cells | 1 | 2008 | 123 | 0.020 |
Why?
| Coculture Techniques | 1 | 2008 | 159 | 0.020 |
Why?
| Cricetinae | 1 | 2008 | 209 | 0.020 |
Why?
| Ovary | 1 | 2008 | 105 | 0.020 |
Why?
| Mineralocorticoids | 1 | 2007 | 2 | 0.020 |
Why?
| Organ Specificity | 1 | 2008 | 126 | 0.020 |
Why?
| Testosterone | 1 | 2008 | 119 | 0.020 |
Why?
| Tissue Inhibitor of Metalloproteinases | 1 | 2007 | 11 | 0.020 |
Why?
| Receptors, Prostaglandin E, EP1 Subtype | 1 | 2007 | 1 | 0.020 |
Why?
| Glomerular Mesangium | 1 | 2007 | 8 | 0.020 |
Why?
| Integrins | 1 | 2007 | 36 | 0.020 |
Why?
| Animals, Genetically Modified | 1 | 2007 | 52 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2008 | 294 | 0.020 |
Why?
| Cobalt | 1 | 2007 | 19 | 0.020 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 17 | 0.020 |
Why?
| Protein Kinase C | 1 | 2007 | 65 | 0.020 |
Why?
| Cyclic GMP | 1 | 2007 | 23 | 0.020 |
Why?
| Heterozygote | 1 | 2007 | 96 | 0.020 |
Why?
| Cell Adhesion | 1 | 2007 | 171 | 0.020 |
Why?
| Transforming Growth Factor beta1 | 1 | 2007 | 66 | 0.020 |
Why?
| Estradiol | 1 | 2008 | 219 | 0.020 |
Why?
| Metalloendopeptidases | 1 | 2007 | 84 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2010 | 1090 | 0.020 |
Why?
| Receptors, Bradykinin | 1 | 2006 | 2 | 0.020 |
Why?
| Drug Combinations | 1 | 2007 | 128 | 0.020 |
Why?
| rho-Associated Kinases | 1 | 2006 | 20 | 0.020 |
Why?
| Drug Synergism | 1 | 2006 | 171 | 0.020 |
Why?
| Viper Venoms | 1 | 2005 | 7 | 0.020 |
Why?
| Microsomes | 1 | 2006 | 45 | 0.020 |
Why?
| Enzyme Induction | 1 | 2006 | 80 | 0.020 |
Why?
| Receptor, Adenosine A1 | 1 | 2005 | 2 | 0.020 |
Why?
| Electric Stimulation | 1 | 2006 | 94 | 0.020 |
Why?
| Uridine Triphosphate | 1 | 2005 | 13 | 0.020 |
Why?
| Fibronectins | 1 | 2005 | 41 | 0.020 |
Why?
| Intracellular Membranes | 1 | 2005 | 26 | 0.020 |
Why?
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 2 | 0.020 |
Why?
| Clofibrate | 1 | 2005 | 7 | 0.020 |
Why?
| Inositol 1,4,5-Trisphosphate | 1 | 2005 | 12 | 0.020 |
Why?
| Potassium Chloride | 1 | 2005 | 18 | 0.020 |
Why?
| Gallic Acid | 1 | 2005 | 6 | 0.020 |
Why?
| Diltiazem | 1 | 2005 | 11 | 0.020 |
Why?
| ortho-Aminobenzoates | 1 | 2005 | 9 | 0.020 |
Why?
| Enzyme Activation | 1 | 2006 | 328 | 0.020 |
Why?
| Calibration | 1 | 2005 | 59 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 151 | 0.020 |
Why?
| Adenosine | 1 | 2005 | 71 | 0.020 |
Why?
| Reactive Oxygen Species | 1 | 2007 | 491 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 2005 | 72 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2005 | 401 | 0.020 |
Why?
| Xanthines | 1 | 2003 | 8 | 0.020 |
Why?
| Furosemide | 1 | 2003 | 9 | 0.020 |
Why?
| Diuretics | 1 | 2003 | 28 | 0.010 |
Why?
| Perfusion | 1 | 2003 | 41 | 0.010 |
Why?
| Chronic Disease | 1 | 2006 | 614 | 0.010 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 24 | 0.010 |
Why?
| Microvilli | 1 | 2002 | 9 | 0.010 |
Why?
| Fluoresceins | 1 | 2002 | 16 | 0.010 |
Why?
| Delayed-Action Preparations | 1 | 2002 | 50 | 0.010 |
Why?
| Dextrans | 1 | 2002 | 20 | 0.010 |
Why?
| Drug Implants | 1 | 2002 | 35 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2005 | 1082 | 0.010 |
Why?
| Protein Isoforms | 1 | 2002 | 124 | 0.010 |
Why?
| Systole | 1 | 2002 | 80 | 0.010 |
Why?
| Reference Values | 1 | 2002 | 354 | 0.010 |
Why?
| Antibodies | 1 | 2002 | 178 | 0.010 |
Why?
| Diet | 1 | 2003 | 598 | 0.010 |
Why?
| Flow Cytometry | 1 | 2002 | 547 | 0.010 |
Why?
|
|
Imig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|